To describe first dose and steady state antiretroviral drug exposure in the female genital tract
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
We did a parallel, three-group, pharmacokinetic evaluation at HIV clinics in Asia (two sites), South...
Despite utilization of potent combination antiretroviral therapy, the incidence of HIV in the U.S. h...
The incidence of HIV remains alarmingly high in many parts of the world. Prophylactic use of antiret...
A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-i...
In the absence of an HIV vaccine or cure, antiretroviral (ARV) based prevention strategies are being...
Background: To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the p...
ABSTRACT We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and...
Antiretrovirals (ARV) that achieve adequate concentrations in anatomical sites of transmission are o...
The exposure of oral antiretroviral (ARV) drugs in the female genital tract (FGT) is variable and al...
Strategies to prevent HIV infection using pre-exposure prophylaxis (PrEP) are required to curtail th...
We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infec...
This study describes first dose and steady state pharmacokinetics of raltegravir (RAL) in cervicovag...
The early closure of a clinical trial assessing the effectiveness of oral antiretroviral pre-exposur...
The objective of the study was to measure antiretroviral exposures in four physiological compartment...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
We did a parallel, three-group, pharmacokinetic evaluation at HIV clinics in Asia (two sites), South...
Despite utilization of potent combination antiretroviral therapy, the incidence of HIV in the U.S. h...
The incidence of HIV remains alarmingly high in many parts of the world. Prophylactic use of antiret...
A previously published study of antiretroviral pharmacokinetics in the female genital tract of HIV-i...
In the absence of an HIV vaccine or cure, antiretroviral (ARV) based prevention strategies are being...
Background: To characterize their potential use in pre-exposure prophylaxis (PrEP) we compared the p...
ABSTRACT We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and...
Antiretrovirals (ARV) that achieve adequate concentrations in anatomical sites of transmission are o...
The exposure of oral antiretroviral (ARV) drugs in the female genital tract (FGT) is variable and al...
Strategies to prevent HIV infection using pre-exposure prophylaxis (PrEP) are required to curtail th...
We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infec...
This study describes first dose and steady state pharmacokinetics of raltegravir (RAL) in cervicovag...
The early closure of a clinical trial assessing the effectiveness of oral antiretroviral pre-exposur...
The objective of the study was to measure antiretroviral exposures in four physiological compartment...
The efficacy of HIV pre-exposure prophylaxis (PrEP) relies on adherence and may also depend on the r...
We did a parallel, three-group, pharmacokinetic evaluation at HIV clinics in Asia (two sites), South...
Despite utilization of potent combination antiretroviral therapy, the incidence of HIV in the U.S. h...
DOI
Add to ORKG